Recent market analysis predicts that the international market for biopharmaceutical bioseparation systems, which is expected to be worth $13 billion in 2022, will increase to $19.6 billion by 2026, growing at a 13.2% compound annual growth rate (CAGR).
According to the analysts, the expanding use of single-use/disposable devices, as well as the growing preference for biopharmaceuticals, equipment developments, and the pharmaceutical industry’s increased focus on production efficiency, are driving an important role in the international bioseparation systems market. Disposable continuous chromatography is one example of a single-use technology that is intended to be more precise and allow for more reliable data interpretation.
The manufacture of biopharmaceutical medications involves a costly, intricate, and time-consuming process called downstream bioprocessing. A greater focus on creating technologies that increase efficiency and reduce costs is encouraging innovation in both current and new solutions. Large bottlenecks in the extraction and purification processes are being caused by improvements in upstream cell culture techniques.
Although there are many other methods or systems for bioseparation, the most popular items on the market for biopharmaceutical bioseparation systems include chromatographic systems, centrifuges, and membranes/filters. There are few options that can equal the output and purity standards of chromatography, which is the main technology utilised in the downstream purification of biopharmaceuticals and continues to be the industry standard.
Chromatography can be used at every stage of the drug development process, from the identification of potential drug candidates to making sure of the purity of dosage forms, evaluating the bioavailability and release time of new drug formulas to establish dosages, and developing manufacturing methods.
In terms of product advancements and innovations, improvements are being made, with a focus on streamlining and optimising current procedures. The market’s chromatography sector is anticipated to expand during 2022 and 2026 at a CAGR of 12.4%.
The development of single-use/disposable technologies constitutes substantial progress in downstream bioprocessing, providing substantial benefits to different phases of bioprocessing, including the elimination of cleaning steps; the reduction of cross-infection risks; increased flexibility and convenience; the reduction of facility set-up times; and the acceleration of turnaround times.
The technologies and procedures themselves are also advancing greatly. Affinity chromatography, for example, is seeing the emergence of alternatives to Protein A-based purification, which is the preferred method but quite expensive. For separating delicate and big molecules, improvements have also been made in HPLC, supercritical fluid chromatography, gas chromatography, electrophoresis, and centrifugation. The emergence of cutting-edge therapeutics like cell-based therapies and individualised medications is also fostering market expansion.
The report claims that despite high demand being anticipated, the market’s growth is constrained by strict regulations controlling the approval of bioseparation systems, high initial investment costs of bioseparation systems, and the availability of substitute technologies like magnetic separation for chromatography. The greatest market for biopharmaceutical bioseparation systems worldwide is in North America. Automated bioseparation systems that can handle several samples at once and with higher levels of accuracy are predicted to rise in popularity in this industry.
Europe is another prosperous market, as the continent is home to several reputable biopharmaceutical firms and is a leader in drug research. The market for biopharmaceutical bioseparation systems in this region is expected to grow as a result of increased government funding, widespread use of high-quality research infrastructure, and increased use of cutting-edge treatment choices.
As incomes rise, healthcare costs rise, and the population grows, the Asia-Pacific marketplace is anticipated to experience the fastest growth in the coming years. Due to cheap labour costs, a number of biopharmaceutical businesses with headquarters in the West intend to establish their manufacturing in Asia-Pacific nations, which will also support market expansion there.